BCKDK and neoplasm: Additionally, overexpression of BCKDK counteracted the anti‐tumor effects of Olaparib or Adriamycin in the breast cancer lines (Figure 4c; Figure S4c,f, Supporting Information) or organoids (Figure 4d; Figure S4d,f, Supporting Information), respectively.